Free Trial
NASDAQ:ANIX

Anixa Biosciences Q2 2025 Earnings Report

Anixa Biosciences logo
$3.38 -0.17 (-4.79%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$3.62 +0.25 (+7.25%)
As of 06/20/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anixa Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Anixa Biosciences' Q2 2025 earnings is scheduled for Friday, September 5, 2025

Earnings Documents

Anixa Biosciences Earnings Headlines

Why Is President Trump Fast-Tracking These Companies?
Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His administration has begun to fast-track the operations of a handful of companies… Accelerating their potential profits.
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

View Anixa Biosciences Profile

More Earnings Resources from MarketBeat